Clinical trials: Breast Cancer - Female
Breast Cancer
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00810797
- Testing
- exemestane, laboratory biomarker analysis, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Decision-aid on Breast Cancer Screening
The present study aim to assess the effect of an interactive web decision aid on informed choice - measured via knowledge, attitudes and intentions concerning breast cancer screening - comparing the decision aid with a standard…
- Trial name
- NCT03097653
- Testing
- Decision-aid, Standard information
- Where
- 7 sites in Italy
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer.
- Trial name
- NCT00121836
- Testing
- Capecitabine, Bevacizumab
- Where
- 57 sites in United States
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2…
- Trial name
- NCT03916744
- Testing
- Giredestrant, Surgery
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 75 people
- Sponsor
- Genentech, Inc.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Breast Neoplasm Female, Postoperative Pain Management
PECS II vs. MTP for Analgesia After MRM
This randomized controlled study aims to compare the analgesic efficacy of the ultrasound-guided modified pectoral nerve block (PECS II) and the midpoint transverse process to pleura (MTP) block in female patients undergoing…
- Trial name
- NCT06187909
- Testing
- PECS II BLOCK, MTP BLOCK
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Ain Shams University
Breast Cancer, Ovarian Cancer
A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
This study will evaluate the efficacy and safety of 6-mercaptopurine (6MP) in combination with methotrexate (MTX) in patients with breast or ovarian cancer who are known to have a BRCA (breast cancer gene) mutation.
- Trial name
- 6MP (NCT01432145)
- Testing
- 6-Mercaptopurine, Methotrexate
- Where
- United Kingdom
- Volunteers
- 74 people
- Sponsor
- University of Oxford
Breast Neoplasms
Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer
RATIONALE: Educational programs may improve coping and quality of life in younger women who have recently been treated for early-stage breast cancer.
- Trial name
- NCT00416572
- Testing
- Education Intervention, Nutrition Education Intervention
- Volunteers
- 252 people
- Sponsor
- Carnegie Mellon University
Breast Cancer, Breast Cancer - Female
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
The purpose of this study is to find out if the investigational drug Ribociclib (LEE011), when taken with standard treatment (Tamoxifen +/- Goserelin) is safe and has beneficial effects in pre-menopausal and post-menopausal women…
- Conditions
- Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
- Trial name
- NCT02586675
- Testing
- Tamoxifen, Ribociclib, Goserelin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer Female
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
This is a prospective multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer.
- Trial name
- POWER (NCT04272801)
- Testing
- tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Shayna Showalter, MD
Breast Cancer
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
- Trial name
- NCT00285857
- Testing
- Lovastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Neoplasms, Breast
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709761
- Testing
- Lapatinib/nab-Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, HER2-negative Breast Cancer
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP FB-9 is a Phase II, multi-center, randomized study of eribulin or weekly paclitaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for women with HER2-negative, operable and locally advanced breast…
- Trial name
- NCT01705691
- Testing
- Paclitaxel, Eribulin, Doxorubicin
- Where
- 20 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- NSABP Foundation Inc
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Breast Cancer
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
The goal of this clinical research study is to learn if and how well eribulin, given in combination with standard chemotherapy, can treat early-stage breast cancer compared to paclitaxel given in combination with standard…
- Trial name
- NCT01593020
- Testing
- Paclitaxel, Eribulin, 5-Fluorouracil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 as a single agent and in combination with palbociclib and/or LHRH agonist.
- Trial name
- NCT01823835
- Testing
- GDC-0810, LHRH Agonist, Palbociclib
- Where
- 14 sites in United States, Netherlands and 2 more
- Volunteers
- 152 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors.
- Trial name
- NCT02460224
- Testing
- LAG525, PDR001
- Where
- 24 sites in United States, Australia and 10 more
- Volunteers
- 490 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.